JP2022545682A5 - - Google Patents

Info

Publication number
JP2022545682A5
JP2022545682A5 JP2022512306A JP2022512306A JP2022545682A5 JP 2022545682 A5 JP2022545682 A5 JP 2022545682A5 JP 2022512306 A JP2022512306 A JP 2022512306A JP 2022512306 A JP2022512306 A JP 2022512306A JP 2022545682 A5 JP2022545682 A5 JP 2022545682A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
igm
variant
motif
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022512306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545682A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/047495 external-priority patent/WO2021041250A1/en
Publication of JP2022545682A publication Critical patent/JP2022545682A/ja
Publication of JP2022545682A5 publication Critical patent/JP2022545682A5/ja
Ceased legal-status Critical Current

Links

JP2022512306A 2019-08-23 2020-08-21 IgMグリコバリアント Ceased JP2022545682A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962891263P 2019-08-23 2019-08-23
US62/891,263 2019-08-23
PCT/US2020/047495 WO2021041250A1 (en) 2019-08-23 2020-08-21 Igm glycovariants

Publications (2)

Publication Number Publication Date
JP2022545682A JP2022545682A (ja) 2022-10-28
JP2022545682A5 true JP2022545682A5 (enExample) 2023-08-16

Family

ID=74684266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022512306A Ceased JP2022545682A (ja) 2019-08-23 2020-08-21 IgMグリコバリアント

Country Status (11)

Country Link
US (1) US20220306760A1 (enExample)
EP (1) EP4017533A4 (enExample)
JP (1) JP2022545682A (enExample)
KR (1) KR20220050166A (enExample)
CN (1) CN114269380A (enExample)
AU (1) AU2020337333A1 (enExample)
BR (1) BR112022003282A2 (enExample)
CA (1) CA3149350A1 (enExample)
IL (1) IL290253A (enExample)
MX (1) MX2022002239A (enExample)
WO (1) WO2021041250A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
JP7179464B2 (ja) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用
AU2016238246B2 (en) 2015-03-25 2021-05-13 Igm Biosciences, Inc. Multi-valent hepatitis B virus antigen binding molecules and uses thereof
CA2999284C (en) 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
WO2020247929A1 (en) 2019-06-07 2020-12-10 Adimab, Llc High affinity anti-cd3 antibodies, and methods for their generation and use
CA3231006A1 (en) * 2021-09-17 2023-03-23 Adimab, Llc Anti-cd3 antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG196697A1 (en) * 2007-03-22 2014-02-13 Biogen Idec Inc Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
EP2496600A1 (en) * 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
IL292311A (en) * 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
CA2999284C (en) * 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
AU2016370821A1 (en) * 2015-12-18 2018-07-12 Biogen Ma Inc. Bispecific antibody platform
EP3571222A4 (en) * 2017-01-19 2021-06-16 Cedars-Sinai Medical Center METHOD BASED ON HIGHLY MULTIPLEX AND MASS SPECTROMETRY FOR MEASURING HUMAN 72 PROTEINS
EP3600442A1 (en) * 2017-03-22 2020-02-05 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
CA3083363A1 (en) * 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies

Similar Documents

Publication Publication Date Title
JP7788113B2 (ja) Ch3ドメインに基づくヘテロダイマー分子、その調製方法及び用途
ES3031036T3 (en) Ch3 modified igg bispecific antibodies and processes for preparation
ES2821753T3 (es) Procedimientos de producción de Fab y de anticuerpos biespecíficos
TWI359028B (en) Bivalent, bispecific antibodies
ES2469791T3 (es) Anticuerpos biespec�ficos bivalentes
JP6247673B2 (ja) 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
CN108601830B (zh) 双特异性抗体平台
EP3487532A1 (en) Modified antigen-binding fab fragments and antigen-binding molecules comprising the same
KR102247704B1 (ko) 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법
JP2020514277A5 (enExample)
JP2024520577A (ja) 抗nkg2a抗体及び組成物
JP2024516098A5 (enExample)
WO2021228091A1 (zh) St2抗原结合蛋白
JP2023076596A (ja) TGF-βRII結合タンパク質
WO2022166977A1 (zh) 抗人il-36r抗体及其应用
TWI857999B (zh) 截斷的多價多元體
JP2024546763A5 (enExample)
JP2024546759A5 (enExample)
WO2022148412A1 (zh) 特异性结合cd47的抗体及其抗原结合片段
CN116867514A (zh) 用于异二聚化的正交突变
JP2022517549A (ja) 二価の二重特異性抗体およびその製造方法、コードする遺伝子、宿主細胞、組成物
ES3040852T3 (en) Engineering charge pair mutations for pairing of hetero-igg molecules
CN119546637A (zh) 与FCγ受体的结合降低的嵌合重链恒定结构域及其用途
US20260098094A1 (en) Cµ4 REGION FOR PAIRING HEAVY AND LIGHT CHAINS IN MULTI-SPECIFIC ANTIBODIES
JP7498747B2 (ja) 抗gm2ap抗体及びその応用